The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Ind-Swift Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.92% INR23.00
America/New_York / 8 mai 2024 @ 04:44
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 245.79 mill |
| EPS: | 5.51 |
| P/E: | 4.17 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 54.16 mill |
| Avg Daily Volume: | 0.262 mill |
| RATING 2024-05-08 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 4.17 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 4.17 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR15.54 (-32.44%) INR-7.46 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 21.00 - 25.00 ( +/- 8.69%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | INR23.00 (-1.92% ) |
| Volume | 0.0065 mill |
| Avg. Vol. | 0.262 mill |
| % of Avg. Vol | 2.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INDSWFTLTD.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
INDSWFTLTD.NS
Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.